Dopavision
Mark Wuttke has a long and varied work experience. Mark began their career in 2001 as a Marketing and Sales Manager at Cognia Corporation. In 2005, they became an Associate at Booz Allen Hamilton (now Booz & Co.). In 2006, they were an Associate at Credit Suisse Securities, and in 2007 they became a Principal at Asten BioPharma Advisors, LLC. From 2010 to 2022, they held various roles at Novartis, including Global Program Head, Global Brand Manager, Ophthalmics Franchise, and Head Portfolio Management and Global Decision Support. Currently, they are the Chief Executive Officer at Dopavision.
Mark Wuttke received a B.S. in Biology from Saint Joseph's University in 1991, after completing their studies there in 1987. Mark then went on to earn their Ph.D. in Biology from Temple University in 1998.
This person is not in any offices
Dopavision
1 followers
The goal of the Berlin-based startup is to develop a clinically validated therapy for myopia progression in children and adolescents. The technology delivers light stimulation to specific photosensitive cells on the retina which in turn modulate dopamine, a neurotransmitter that is important for the regulation of eye growth. Founded in 2017, Dopavision GmbH is supported by the German government via the “Industrie-in-Klinik” program of the BMBF (Federal Ministry of Education and Research) with the amount of € 1.4 million over three years. Additionally, the company is backed with venture capital in a seed round to advance the research and further develop the product for clinical validation.